

Supplementary Table S1. Chemotherapy regimens for breast cancer[38,39]

	Regimens for HER2-negative breast cancer	Regimens for HER2-positive breast cancer
Preoperative/Adjuvant Therapy Regimens	TC (docetaxel plus cyclophosphamide)	TH (paclitaxel and trastuzumab)
	AC-T, dose dense (doxorubicin plus cyclophosphamide followed by paclitaxel)	TCH (docetaxel, carboplatin, and trastuzumab)
	AC (doxorubicin plus cyclophosphamide)	TCHP (trastuzumab, pertuzumab, carboplatin, and docetaxel)
	TAC (docetaxel, doxorubicin, and cyclophosphamide)	AC-TH (doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab)
	Oral CMF (oral cyclophosphamide plus methotrexate and fluorouracil)	AC-THP (doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab)
	IV CMF (IV cyclophosphamide plus methotrexate and fluorouracil)	FEC-THP (FEC followed by docetaxel, pertuzumab, and trastuzumab)
	FEC (fluorouracil, epirubicin, plus cyclophosphamide)	THP-FEC-H (neoadjuvant docetaxel, trastuzumab, and pertuzumab followed by adjuvant FEC, followed by trastuzumab)
	FEC followed by weekly paclitaxel	THP (docetaxel/paclitaxel, trastuzumab, and pertuzumab)
	FEC followed by weekly docetaxel	
	TC (paclitaxel and carboplatin)	
	EC (epirubicin and cyclophosphamide)	
	Anthracyclines (doxorubicin and liposomal doxorubicin)	THP (pertuzumab, trastuzumab and docetaxel)
Recurrent/Metastatic Therapy Regimens	Taxanes (paclitaxel)	THP (trastuzumab and Pertuzumab and paclitaxel/docetaxel)
	Anti-metabolites (capecitabine and gemcitabine)	Ado-trastuzumab emtansine (T-DM1)
	Microtubule inhibitors (vinorelbine and eribulin)	Fam-trastuzumab deruxtecan-nxki
	Sacituzumab govitecan-hziy	Tucatinib and trastuzumab and capecitabine
	Cyclophosphamide	Trastuzumab and docetaxel or vinorelbine

Docetaxel	Trastuzumab and paclitaxel and or capecitabine
Albumin-bound paclitaxel	Capecitabine and trastuzumab or lapatinib
Epirubicin	Trastuzumab and lapatinib
Ixabepilone	Neratinib and capecitabine
AC	Margetuximab-cmkb and capecitabine
(doxorubicin and cyclophosphamide)	or eribulin or gemcitabine or vinorelbine
EC	
(epirubicin and cyclophosphamide)	
CMF	
(cyclophosphamide, methotrexate and fluorouracil)	
Docetaxel/capecitabine	
GT	
(gemcitabine and paclitaxel)	
Gemcitabine/carboplatin	
Carboplatin plus paclitaxel or albumin-bound paclitaxel	

References:

38. Gradishar, W. J.; M. S. Moran; J. Abraham; R. Aft; D. Agnese; K. H. Allison; B. Anderson; H. J. Burstein; H. Chew and C. Dang. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 20 **2022**, 691-722.
39. Gradishar, W. J. NCCN guidelines updates: Management of patients with her2-negative breast cancer. Journal of the National Comprehensive Cancer Network 20 **2022**, 561-65.